
The brief / AI in science · AI business
OpenAI acquires Orchestra Bio to help coordinate drug development
Orchestra helps drug-development teams track studies and delays. OpenAI plans to combine it with its Rosalind research tools.
OpenAI says it has acquired Orchestra Bio, which makes software to help drug-development teams keep track of studies, deadlines and work spread across different departments and partners.
A failed batch of medicine, for example, could delay a clinical trial. OpenAI says Orchestra’s AI agents can help identify which plans are affected, collect the relevant information and compare ways to respond. Scientists and program leaders decide what to do next.
OpenAI plans to combine Orchestra’s team and technology with Rosalind, its AI models and tools for life sciences research. The aim is to connect work such as analyzing scientific results with the studies and decisions needed to develop a potential treatment. OpenAI’s announcement
The acquisition gives OpenAI software for coordinating that work alongside its research tools. It has not disclosed a purchase price or detailed timetable for bringing them together. Getting treatments to patients sooner is the stated goal; the announcement does not demonstrate that result.